Compare GMAB & CNH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMAB | CNH |
|---|---|---|
| Founded | 1999 | 1842 |
| Country | Denmark | United Kingdom |
| Employees | 3029 | 34197 |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 13.6B |
| IPO Year | N/A | N/A |
| Metric | GMAB | CNH |
|---|---|---|
| Price | $26.84 | $10.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $39.81 | $13.00 |
| AVG Volume (30 Days) | 1.6M | ★ 16.0M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.95% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.85 | N/A |
| Revenue Next Year | $16.04 | $8.21 |
| P/E Ratio | ★ $1.90 | $31.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.89 | $9.00 |
| 52 Week High | $35.43 | $13.87 |
| Indicator | GMAB | CNH |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 39.24 |
| Support Level | $24.95 | $9.84 |
| Resistance Level | $29.64 | $11.16 |
| Average True Range (ATR) | 0.57 | 0.38 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 3.40 | 2.47 |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
CNH Industrial is the world's second largest manufacturer of agricultural machinery (82% of industrial net sales) as well as a major player in construction equipment (18% of industrial net sales). Its Case and New Holland brands have served farmers for generations. Geographically, agriculture sales are 40% North America, 32% Europe, Middle East, and Africa, 18% South America, and 10% Asia-Pacific. CNH's products are available through a robust independent dealer network, which includes over 2,600 dealer and distribution locations and reach into 164 countries. The construction business leverages over 400 dealers. The company's captive finance arm provides retail financing to its customers as well as wholesale financing for dealers to maintain inventory, which supports sales.